Last reviewed · How we verify
NCT06085976
Efficacy and Safety of Octreotide in Laparoscopic Hepatectomy Surgery: Effect on Blood Loss, Need for Vasoactive Drugs, Transfusion Requirements.
Phase 2 trial testing Octreotide in Hepatic Carcinoma in 62 participants. Status unknown.
14 August 2025
Quick facts
| Lead sponsor | Clinica Universidad de Navarra, Universidad de Navarra |
|---|---|
| Phase | Phase 2 |
| Status | Status unknown |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | double |
| Primary purpose | prevention |
| Enrollment | 62 |
| Start date | 14 August 2023 |
| Primary completion | 14 August 2025 |
| Estimated completion | 30 November 2025 |
| Sites | 1 location across Spain |
Drugs / interventions tested
- Octreotide (OCTREOTIDE) — full drug profile →
- Placebo
Conditions studied
- Hepatic Carcinoma — all drugs for Hepatic Carcinoma →
- Hepatic Metastasis — all drugs for Hepatic Metastasis →
Sponsor
Clinica Universidad de Navarra, Universidad de Navarra
Who can join
Adults 18 to 80, any sex, with Hepatic Carcinoma or Hepatic Metastasis. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The goal of this double-blind clinical trial is to compare the efficacy of octreotide versus placebo in laparoscopic hepatectomy surgery in patients diagnosed with resectable hepatocarcinoma or liver metastases. The main questions it aims to answer are: * Decrease in intraoperative bleeding measured in ml of blood lost. * Decrease in the need for blood transfusion and use of intraoperative vasoactive drugs. Participants will receive octreotide or placebo after signing the informed consent form.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT06085976
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Octreotide
Trials testing the same drug.
- NCT06865677 — Sacituzumab Govitecan for Relapsed Ovarian, Endometrial, and Cervical Carcinomas · Phase 2 · terminated
- NCT04048707 — Angiotensin 2 for Hepatorenal Syndrome · Phase 2 · withdrawn
- NCT04028323 — Functional MRI-based Assessment of Terlipressin vs. Octreotide on Renal Function in Cirrhotic Patients With Acute Varice · Phase 4 · unknown
- NCT04027348 — Palliative Management of Inoperable Malignant Bowel Obstruction · Phase 2 · terminated
- NCT03846180 — Terlipressin on Effect of Renal Function in Cirrhotic Patients With Acute Gastrointestinal Hemorrhage · completed
Other recruiting trials for Hepatic Carcinoma
Currently open trials in the same condition.
- NCT07359586 — Laryngopharyngeal Injury After Endotracheal Intubation Under General Anesthesia · recruiting
- NCT06342414 — An Exosome-Based Liquid Biopsy for the Differential Diagnosis of Primary Liver Cancer · recruiting
- NCT04220944 — Combined Locoregional Treatment With Immunotherapy for Unresectable HCC. · Phase 1 · active not recruiting
Other Clinica Universidad de Navarra, Universidad de Navarra trials
Trials by the same sponsor.
- NCT07370571 — NO AXILLARY SURGERY IN EARLY BREAST CANCER (OXIGENATE) · not yet recruiting
- NCT07165431 — Effect of a Postbiotic Supplementation in Overweight and Obese Subjects: A Randomized Controlled Trial (PARABIOTICS-2). · NA · recruiting
- NCT07447440 — Role of Pro-Resolving Lipid Mediators in Obesity-Associated Diseases · recruiting
- NCT07191210 — Co-Designed Comprehensive Transition Programme for First-Line Nurse Managers · NA · not yet recruiting
- NCT07132060 — MRI-guided Dose Intensification Program Locally Advanced Pancreatic Cancer · NA · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06085976 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Clinica Universidad de Navarra, Universidad de Navarra
- Last refreshed: 17 October 2023
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06085976.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing